<SEC-DOCUMENT>0001193125-16-770355.txt : 20161117
<SEC-HEADER>0001193125-16-770355.hdr.sgml : 20161117
<ACCEPTANCE-DATETIME>20161117084302
ACCESSION NUMBER:		0001193125-16-770355
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20161117
FILED AS OF DATE:		20161117
DATE AS OF CHANGE:		20161117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		162003893

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d298448d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of November 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: 001-36697 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DBV
TECHNOLOGIES S.A. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>177-181 avenue Pierre Brossolette </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92120 Montrouge France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9746;&nbsp;&nbsp;Form
20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Form 40-F </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST</U></B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated November&nbsp;17, 2016.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>DBV TECHNOLOGIES S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;17, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Schilansky</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name&nbsp;&nbsp;David Schilansky</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:&nbsp;&nbsp;&nbsp;Chief Operating Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g298448g1116145515427.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">


<IMG SRC="g298448g1116145515333.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">


<IMG SRC="g298448g1116145515536.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT
for Booster Vaccination Against Pertussis </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DSMB expressed no safety concerns with Viaskin rPT 25 &micro;g </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following positive DSMB review, dosing with Viaskin rPT 50 &micro;g has been initiated </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PARIS, BANGKOK and GENEVA November 17, 2016 - </B>DBV Technologies (Euronext: DBV &#150; ISIN: FR0010417345 &#150; Nasdaq Stock Market: DBVT), the Geneva
University Hospitals (HUG) and BioNet-Asia Co. Ltd today announced that in a planned interim assessment of the Phase I trial of Viaskin rPT for booster immunization against Bordetella pertussis, the independent Data and Safety Monitoring Board
(DSMB) concluded that there were no safety concerns with the administration of Viaskin rPT 25 &#371;g in the first subject cohort. Based on this review, enrollment in the trial has continued as planned, with dosing of Viaskin rPT 50 &#371;g
commencing in the second subject cohort. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Viaskin rPT pertussis booster vaccination program intends to test the ability of DBV&#146;s needleless and
adjuvant-free patch technology, Viaskin, to epicutaneously deliver two different doses of BioNet&#146;s genetically detoxified, recombinant pertussis toxin for boosting immunity against whooping cough. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first dosing cohort, subjects received two applications of either Viaskin rPT 25 &#371;g or placebo. Following the DSMB&#146;s positive recommendation,
a second cohort of subjects will receive two applications of Viaskin rPT 50 &#371;g or placebo at two-week interval. This Phase&nbsp;I proof of concept study is being conducted under the supervision of Professor Claire-Anne Siegrist from the
Clinical Research Center of HUG and is sponsored by DBV Technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Phase I Viaskin rPT Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Phase I dose-escalation, randomized, double-blind, placebo-controlled safety and immunogenicity study is assessing the safety of BioNet&#146;s
genetically-detoxified recombinant pertussis toxin administered by DBV&#146;s Viaskin patches in 60 young healthy adults. Secondary endpoints will assess the patients&#146; humoral responses elicited by Viaskin rPT 25 &micro;g and 50 &micro;g
compared to placebo. Immune cellular responses will also be monitored as exploratory endpoints. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trial is being conducted in the Clinical Research
Center of the Geneva University Hospitals. Men and women aged 18 to 40 years who have been vaccinated during childhood against pertussis will be randomized into two cohorts of 30 subjects each. The Viaskin patches will be applied for 48 hours, with
a two-week interval between applications. Four weeks after the second Viaskin application, participants will receive one dose of Boostrix<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> dTpa vaccine to ensure the recall of immunity against
diphtheria, tetanus and the three pertussis antigens (only a single antigen will be delivered through Viaskin rPT). All subjects will be observed after each application. Local and systemic adverse events will be monitored.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first cohort has received two applications of Viaskin rPT 25 &#371;g or placebo. Following a positive DSMB review, dosing in the second patient cohort,
which is expected to receive two applications of Viaskin rPT 50 &#371;g or placebo has commenced. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Bordetella Pertussis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pertussis, commonly known as whooping cough, is a highly contagious respiratory illness caused by a type of bacteria known as&nbsp;Bordetella pertussis.
Pertussis vaccination is recommended as part of routine childhood immunization. Although the incidence of pertussis has declined as a result of immunization of infants and young children, vaccine-induced immunity does not persist for long.&nbsp;This
phenomenon, known as waning immunity, has increased since the introduction of acellular pertussis vaccines in 1996, which tend to provide short-lived protection against the Bordetella pertussis bacteria. According to the U.S. Centers for Disease
Control and Prevention (CDC), there are 16 million pertussis cases worldwide each year, mainly in adolescents and adults who often can infect infants who have not yet completed their pertussis immunization. In these young patients, pertussis can be
severe and fatal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Booster immunizations are now recommended for adolescents and adults, but compliance is not always high. A new vaccine technology that
is patient-friendly, painless and non-invasive could help increase the compliance for booster immunization against whooping cough. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DBV
Technologies</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies is developing Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, DBV&#146;s method of delivering biologically active compounds to the immune system
through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV&#146;s food
allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic
Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies has global headquarters in
Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares
(each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: <U>www.dbv-technologies.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Geneva University Hospitals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Geneva University
Hospitals (HUG), reference academic institution at both national and international level, gather eight public hospitals of Geneva. Their centres of excellence cover hepato-biliary and pancreatic diseases, cardiovascular diseases, oncology,
musculoskeletal and sports medicine, old age medicine, genetic medicine and vaccinology. Its Center of Vaccinology, led by Professor Claire-Anne Siegrist, gained international recognition through the performance of a large first-in-humans Phase I
randomized clinical trial that enrolled 115 subjects to characterize the safety and immunogenicity of the VSV-ZEBOV Ebola vaccine candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With their
10,500 employees, the HUG welcome each year 60,000 hospitalized patients and assure 91,000 emergencies, 990,000 consultations or ambulatory care and 26,000 surgical procedures. More than 800 physicians, 3,000 interns and 150 apprentices perform
their training here. The HUG are working closely with the Faculty of Medicine of the University of Geneva and WHO in various training and research projects. They develop partnerships with CHUV, EPFL, CERN and other actors from the Lemanic Health
Valley. More information on: <U>www.hug-ge.ch</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About BioNet-Asia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioNet-Asia offers access to vaccine and technology through biotech innovation and partnering networks. BioNet has built several international partnerships
fostering vaccine self-reliance and leading to the supply of billions of doses of vaccines worldwide. BioNet has also a broad pipeline of vaccines in R&amp;D and clinical stages. BioNet most advanced program is the development of a new generation of
pertussis vaccines aimed at overcoming the waning immunity observed with the conventional acellular pertussis vaccines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioNet&#146;s pertussis vaccines
are produced from a new proprietary <I>Bordetella pertussis</I> strain expressing genetically detoxified Pertussis Toxin (PTgen&#153;). The unique properties of BioNet&#146;s PTgen enables the vaccines to induce superior anti-PT immune response. For
additional information, please visit <U>www.bionet-asia.com</U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements about the potential safety and efficacy of Viaskin as a means of delivering
recombinant pertussis toxin to boost immunity against Bordetella pertussis.&nbsp;These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties.&nbsp;The Company&#146;s product candidates have not
been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and
related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results.&nbsp;A
further list and description of these risks, uncertainties and other risks can be found in the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory filings with the French Autorit&eacute; des March&eacute;s Financiers, the Company&#146;s Securities and Exchange Commission filings and reports, including in the Company&#146;s Annual
Report on Form 20-F for the year ended December 31, 2015 and future filings and reports by the Company.&nbsp;Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the
date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Technologies Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Susanna Mesa </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President, Strategy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1&nbsp;212-271-0861 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">susanna.mesa@dbv-technologies.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Erinn White, Centron PR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1-646-722-8822 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ewhite@centronpr.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact Europe </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Caroline Carmagnol, Alize RP, Relations Presse </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+33 (0)6
64 18 99 59</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">caroline@alizerp.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Geneva University
Hospitals Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Professor Claire-Anne Siegrist, Director of the Center of Vaccinology </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+41(22) 379 57 77 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">claire-anne.siegrist@unige.ch </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HUG Media Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nicolas de Saussure, PR Officer
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+41&nbsp;(22)&nbsp;372&nbsp;60&nbsp;06 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">nicolas.desaussure@hcuge.ch </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BioNet Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Laurent Dapremont, Director Strategic Business Development, BioNet-Asia Co. Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+66 (2) 361 8110 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">laurent.d@bionet-asia.com</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g298448g1116145515333.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g298448g1116145515333.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U .,# 2(  A$! Q$!_\0
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MC\)Z:ARPED_WG_PK3MM.L[,?N+=$]P.:**5RHTH1V1:HHHH+$*AAA@"/<4
M#   ]***    8  %+110 F #D 9-+110 F!G.!GUI:** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g298448g1116145515427.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g298448g1116145515427.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !R &4# 2(  A$! Q$!_\0
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M-W/Z"MW0?#L.C(\TCFYU";F>Y?JQ]!Z"KVG:79:3;"WLK=8D[XZL?4GO5R@
MHHHH **** "BBB@ HKCYM2U7Q)JEQ8Z-.+2QMFV37@&69O1:G?P[K=JHFL?$
M5U+.@SY=T-T;^WM0!8M-0NI/'6H6#S$VL5JCI'@8#'&3^M-?4+L>/H]/$Q^R
MFT,ACP,;N>:R?#%]+J/C?49Y[<V\XM5CEB)^ZRD _A4>O7MS8^/HGLH//NI+
M011(3QN)/)]A0!WM%<LGAS6;A#+>>);M+AQRMN L:GV'?]*ALM4U30M9@TK6
MYEN;>XXMKS&#GT:@#KZ*Y?Q+>WFBZKIVIK<2?V>S^3<PY^49Z-_GTKIP05#
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M)((H5DC&SGS/+PRG/5<<"E:(_>-"BBBH+"BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g298448g1116145515536.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g298448g1116145515536.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D /$# 2(  A$! Q$!_\0
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M6I0 4444 %%%% !1110 5X7>_P#'_<_]=6_F:]TKPN]_X_[C_KJW\S7LY/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
